Genus plc to Hold Capital Markets Event Today at 10:00 AM ET and Provide Update on its Porcine PRRSv Resistance Program
22 Junho 2021 - 3:00AM
Business Wire
Initial trial results on Genus’ gene edited
pigs indicate 100% resistance to two strains of PRRS virus
Genus plc (LSE: GNS), a leading global animal genetics company,
is hosting a Capital Markets Event (CME) today at 10 AM ET, 3pm UK
time. The CME will cover key strategic progress and initiatives
being implemented to further strengthen Genus’s leadership in the
animal genetics market. The presentations given by members of
Genus's executive management will be made available on the Company
website after the event at:
https://www.genusplc.com/investors/results-reports-and-presentations/.
https://www.genusplc.com/media/1787/genus-capital-markets-event-jun2021-presentation.pdf
As part of the CME, Genus’s Chief Scientific Officer Dr. Elena
Rice will provide an update on Genus’s porcine reproductive and
respiratory syndrome virus (‘PRRSv’) resistance programme,
including the results of the most recent disease challenge for
Genus’s gene edited pigs. In the most recent trial, 40 animals (23
gene edited for PRRS resistance and 17 unedited animals), which
were infected with two prevalent strains of the PRRS virus, were
tested. The trial demonstrated that the gene edited pigs were 100%
resistant to both strains of the PRRS virus, and confirms previous
academic findings. In the next phase of the disease trials, Genus
will be evaluating whether PRRSv resistance is preserved across
generations by breeding and testing the offspring of the first
generation of edited pigs. These trials will be included as part of
the submissions to the US Food and Drug Administration as part of
the regulatory review process.
Any institutional investors and sell side analysts not already
registered and wishing to attend the event should contact Buchanan
at genus@buchanan.uk.com.
About Genus
Genus is a world-leading animal genetics company. Genus creates
advances to animal breeding and genetic improvement by applying
biotechnology and sells added value products for livestock farming
and food producers. Its technology is applicable across livestock
species and is currently commercialised by Genus in the dairy, beef
and pork food production sectors.
Genus’s worldwide sales are made in over seventy-five countries
under the trademarks ‘ABS’ (dairy and beef cattle) and 'PIC' (pigs)
and comprise semen, embryos and breeding animals with superior
genetics to those animals currently in farms. Genus's customers’
animals produce offspring with greater production efficiency, and
quality, and use these to supply the global dairy and meat supply
chains.
The Group's competitive edge has been created from the ownership
and control of proprietary lines of breeding animals, the
biotechnology used to improve them and its global supply chain,
technical service and sales and distribution network.
With headquarters in Basingstoke, United Kingdom, Genus
companies operate in over twenty-five countries on six continents,
with research laboratories located in Madison, Wisconsin, USA.
Forward-looking Statements
This Announcement may contain, and the Company may make verbal
statements containing “forward-looking statements” with respect to
certain of the Company’s plans and its current goals and
expectations relating to its future financial condition,
performance, strategic initiatives, objectives and results. Readers
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this Announcement.
Forward-looking statements sometimes use words such as “aim”,
“anticipate”, “target”, “expect”, “estimate”, “intend”, “plan”,
“goal”, “believe”, “seek”, “may”, “could”, “outlook”, “will” or
other words of similar meaning. By their nature, all
forward-looking statements involve risk and uncertainty because
they relate to future events and circumstances which are beyond the
control of the Company, including amongst other things, diverse
factors such as domestic and global economic business conditions,
market-related risks such as fluctuations in commodity prices,
interest rates and exchange rates, the policies and actions of
governmental and regulatory authorities, the effect of competition,
inflation, deflation, the timing effect and other uncertainties of
future acquisitions or combinations within relevant industries, the
rate of on-going porcine re-stocking in China after African Swine
Fever, the continued development and improvement of our IntelliGen®
technology, the development and registration of our innovative new
products, such as our gene edited porcine reproductive and
respiratory syndrome virus resistant pigs, the continued growth in
emerging markets, the effect of tax and other legislation and other
regulations in the jurisdictions in which the Company and its
respective affiliates operate, the effect of volatility in the
equity, capital and credit markets on the Company’s profitability
and ability to access capital and credit, a decline in the
Company’s credit ratings; the effect of operational risks; and the
loss of key personnel. As a result, the actual future financial
condition, performance and results of the Company may differ
materially from the plans, goals and expectations set forth in any
forward-looking statements. Except as required by applicable law or
regulation, the Company expressly disclaims any obligation or
undertaking to publish any updates or revisions to any
forward-looking statements contained in this Announcement to
reflect any changes in the Company’s expectations with regard
thereto or any changes in events, conditions or circumstances on
which any such statement is based.
No statement in this Announcement is intended to be a profit
forecast, and no statement in this Announcement should be
interpreted to mean that earnings per share of the Company for the
current or future financial years would necessarily match or exceed
the historical published earnings per share of the Company.
Information contained in this Announcement should not be relied
upon as a guide to the Company’s future performance.
This announcement is available on the Genus website
www.genusplc.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210621005858/en/
Genus plc Stephen Wilson, Chief Executive Officer Alison
Henriksen, Chief Financial Officer Tel: +44 1256 345970
Investor Relations and Media Contacts: United Kingdom
Buchanan Charles Ryland / Chris Lane / Sophie Wills Tel: +44
207 466 5000
United States LaVoieHealthScience Jim Heins Tel: +1
617-374-8800 jheins@lavoiehealthscience.com
Genus (LSE:GNS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Genus (LSE:GNS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024